Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.66 USD | +1.99% | +7.42% | -14.94% |
12/03 | LifeStance Health Appoints Teresa DeLuca to Its Board of Directors | CI |
06/03 | Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating | MT |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 48% by 2026.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is highly valued given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.94% | 2.55B | D+ | ||
+13.70% | 81.4B | C+ | ||
-29.20% | 70.18B | B- | ||
+9.72% | 29.08B | C+ | ||
-11.43% | 16.97B | B | ||
-0.43% | 16.96B | A- | ||
-0.31% | 15.26B | A- | ||
+3.42% | 12.41B | A- | ||
-30.70% | 11.95B | - | - | |
-6.75% | 11.93B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LFST Stock
- Ratings LifeStance Health Group, Inc.